Overview

* Zura Bio ( ZURA ) Q3 net loss narrows to $20 mln, down from $22.9 mln last year

* R&D expenses rise to $11.9 mln in Q3, reflecting tibulizumab trial advancement

Outlook

* Zura Bio expects topline data from tibulizumab trials in H2 2026

* Company anticipates cash to fund operations through 2027

* Zura Bio ( ZURA ) monitoring timelines and strategies for clinical studies

Result Drivers

* TIBULIZUMAB TRIALS - Advancement of Phase 2 trials for tibulizumab in HS and SSc drove increased R&D expenses

* STUDY EXECUTION - Focus on disciplined study execution and patient enrollment for tibulizumab trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.21

Q3 Net -$18.04

Income mln

Q3 -$19.52

Income mln

from

Operatio

ns

Q3 $19.52

Operatin mln

g

Expenses

Q3 -$18.04

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Zura Bio Ltd ( ZURA ) is $13.50, about 65.7% above its November 12 closing price of $4.63

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)